IMR Press / RCM / Special Issues / 1637668923004

Antiplatelet Therapy in Cardiovascular Disease

Submission deadline: 30 May 2022
Special Issue Editors
Domenico D'Amario, MD, PhD
Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
Interests: Cardiac imaging; Stress-echocardiography; Contrast-echocardiography; Computed tomography imaging
Mattia Galli, MD
Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
Interests: Heart failure; Clinical cardiology; Atrial fibrillation; Myocardial infarction; Cardiovascular medicine
Special Issue Information

Dear Colleagues,

Several new technologies and medications have been introduced for the treatment and prevention of cardiovascular (CV) disease over the past recent years. Despite this, the high incidence of ischemic events is still a major concern in modern medicine and is responsible for a large number of hospitalizations and deaths worldwide. Antiplatelet therapy is key to reducing ischemic events amongst patients with CV disease, but is inevitably associated with increased bleeding. A better understanding of the prognostic implications associated with bleeding, together with the reduced thrombogenicity of stent platforms and devices, have led to a substantial evolution in antiplatelet treatment regimens over the past decades. Numerous studies have been conducted to better stratify patients with CV disease according to their ischemic and bleeding risks and to then implement antithrombotic regimens accordingly. Evidence from this research has led to the development of several antithrombotic treatment options, as recommended by recent Guidelines.

Suggested sub-topics
- Strategies for prevention and management of bleeding among patients with cardiovascular disease
- Tailoring antiplatelet therapy in patients undergoing PCI: current evidence and practical recommendations

Dr. Domenico D'Amario and Dr. Mattia Galli
Guest Editors

Keywords
Antiplatelet therapy
Bleeding
Thrombosis
Percutaneous coronary intervention
P2Y12 inhibitors
Cardiovascular disease
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Planned Paper (6 Papers)
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to IMR Press journals will subject to peer-review before acceptance

Bleeding Complications in Patients Undergoing Percutaneous Coronary Intervention

Mattia Galli, Renzo Laborante, Domenico D'Amario

Long-term Antithrombotic Therapy in Secondary Prevention in Patients with Atherosclerotic Cardiovascular Disease

Francesco Cannata, Mauro Chiarito, Jorge Sanz-Sanchez, Giulio Stefanini

P2Y12 Inhibitor Monotherapy: Considerations for Acute and Long-term Secondary Prevention Post-PCI

Xuan Zhou, Francesco Franchi, Dominick Angiolillo

Antithrombotic Therapy for Patients Undergoing Drug-coated Balloon PCI: State of the Art and Future Directions

Cortese B et al.

Dual Antiplatelet Therapy in Elderly Patients undergoing Percutaneous Coronary Intervention

Alberto Monello, Cosmo Godino

Reversal of Platelet Inhibition in Patients Receiving Ticagrelor

Piotr Adamski, Jacek Kubica

Published Paper (1 Paper)
Open Access Original Research
Primary Causes of Death Reported to the FDA Suggest Less Ticagrelor Mortality Benefit than the List Issued to the PLATO Trial Investigators
Victor Serebruany, Jean-Francois Tanguay, Thomas Marciniak
Rev. Cardiovasc. Med. 2022, 23(4), 132; https://doi.org/10.31083/j.rcm2304132
(This article belongs to the Special Issue Antiplatelet Therapy in Cardiovascular Disease)
11
Download
45
Views
Back to top